Enhanced antitumor efficacy and counterfeited cardiotoxicity of combinatorial oral therapy using Doxorubicin- and Coenzyme Q10-liquid crystalline nanoparticles in comparison with intravenous Adriamycin

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 10, Issue 6, 2014, Pages 1231-1241

  Swarnakar, Nitin K ^a   Thanki, Kaushik ^a   Jain, Sanyog ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

CoQ10; DMBA induced breast cancer model; Dox; Liquid crystalline nanoparticles

Indexed keywords

CRYSTALLINE MATERIALS; NANOPARTICLES; TUMORS;

ANTI-TUMOR EFFICACY; BREAST CANCER MODELS; CONVENTIONAL METHODS; COQ10; DOX; LIQUID CRYSTALLINE NANOPARTICLES; RESIDUAL TUMORS; THERAPEUTIC EFFICACY;

LIQUIDS;

DOXORUBICIN; DOXORUBICIN LIQUID CRYSTALLINE NANOPARTICLE; NANOPARTICLE; SOLVENT; UBIDECARENONE; UBIDECARENONE LIQUID CRYSTALLINE NANOPARTICLE; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIBIOTIC; UBIQUINONE; VITAMIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; CYTOTOXICITY; DIFFUSION; DRUG EFFICACY; DRUG POTENTIATION; EVAPORATION; HUMAN; HUMAN CELL; MCF 7 CELL LINE; TUMOR VOLUME; ANALOGS AND DERIVATIVES; ANIMAL; BREAST NEOPLASMS; CHEMISTRY; COMPARATIVE STUDY; DRUG COMBINATION; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; LIQUID CRYSTAL; ORAL DRUG ADMINISTRATION; SPRAGUE DAWLEY RAT; TUMOR CELL LINE;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; CARDIOTOXICITY; CELL LINE, TUMOR; DOXORUBICIN; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LIQUID CRYSTALS; NANOPARTICLES; RATS, SPRAGUE-DAWLEY; UBIQUINONE; VITAMINS;

EID: 84905283740     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2014.03.003     Document Type: Article

References (44)

1. Takemura G., Fujiwara H. Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis 2007, 49:330-352.
2. Pigram W.J., Fuller W., Hamilton L.D. Stereochemistry of intercalation: interaction of daunomycin with DNA. Nat New Biol 1972, 235:17-19.
3. Sangeetha P., Das U.N., Koratkar R., Suryaprabha P. Increase in free radical generation and lipid peroxidation following chemotherapy in patients with cancer. Free Radic Biol Med 1990, 8:15-19.
4. De Beer E.L., Bottone A.E., Voest E.E. Doxorubicin and mechanical performance of cardiac trabeculae after acute and chronic treatment: a review. Eur J Pharmacol 2001, 415:1-11.
5. Ryberg M., Nielsen D., Skovsgaard T., Hansen J., Jensen B.V., Dombernowsky P. Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. J Clin Oncol 1998, 16:3502-3508.
6. Kappus H., Reinhold C. Inhibition of bleomycin-induced toxic effects by antioxidants in human malignant melanoma cells. Adv Exp Med Biol 1990, 264:345-348.
7. Aberg F., Appelkvist E.L., Broijersen A., Eriksson M., Angelin B., Hjemdahl P., et al. Gemfibrozil-induced decrease in serum ubiquinone and alpha- and gamma-tocopherol levels in men with combined hyperlipidaemia. Eur J Clin Invest 1998, 28:235-242.
8. Jung H.J., Park E.H., Lim C.J. Evaluation of anti-angiogenic, anti-inflammatory and antinociceptive activity of coenzyme Q(10) in experimental animals. J Pharm Pharmacol 2009, 61:1391-1395.
9. Premkumar V.G., Yuvaraj S., Sathish S., Shanthi P., Sachdanandam P. Anti-angiogenic potential of coenzyme Q10, riboflavin and niacin in breast cancer patients undergoing tamoxifen therapy. Vasc Pharmacol 2008, 48:191-201.
10. Thanki K., Gangwal R.P., Sangamwar A.T., Jain S. Oral delivery of anticancer drugs: challenges and opportunities. J Control Rel 2013, 170:15-40.
11. Banna G.L., Collova E., Gebbia V., Lipari H., Giuffrida P., Cavallaro S., et al. Anticancer oral therapy: emerging related issues. Cancer Treat Rev 2010, 36:595-605.
12. Bhagavan H.N., Chopra R.K. Coenzyme Q10: absorption, tissue uptake, metabolism and pharmacokinetics. Free Radic Res 2006, 40:445-453.
13. Kalaria D.R., Sharma G., Beniwal V., Ravi Kumar M.N. Design of biodegradable nanoparticles for oral delivery of doxorubicin: in vivo pharmacokinetics and toxicity studies in rats. Pharm Res 2009, 26:492-501.
14. Miles M.V. The uptake and distribution of coenzyme Q (10). Mitochondrion 2007, 7:S72-S77.
15. Lockwood K., Moesgaard S., Hanioka T., Folkers K. Apparent partial remission of breast cancer in 'high risk' patients supplemented with nutritional antioxidants, essential fatty acids and coenzyme Q10. Mol. Aspects Med. 1994, 15(Suppl.):s231-s240.
16. Swarnakar N.K., Jain V., Dubey V., Mishra D., Jain N.K. Enhanced oromucosal delivery of progesterone via hexosomes. Pharm Res 2007, 24:2223-2230.
17. Swarnakar NK, Thanki K, Jain S. Bicontinuous cubic liquid crystalline nanoparticles for oral delivery of doxorubicin: implications on bioavailability, therapeutic efficacy and cardiotoxicity. Pharm. Res. 2013; In press. doi:10.1007/s11095-013-1244-8.
18. Nguyen T.H., Hanley T., Porter C.J., Larson I., Boyd B.J. Phytantriol and glyceryl monooleate cubic liquid crystalline phases as sustained-release oral drug delivery systems for poorly water soluble drugs I. Phase behaviour in physiologically-relevant media. J Pharm Pharmacol 2010, 62:844-855.
19. Porter C.J., Trevaskis N.L., Charman W.N. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov 2007, 6:231-248.
20. Nguyen T.H., Hanley T., Porter C.J., Larson I., Boyd B.J. Phytantriol and glyceryl monooleate cubic liquid crystalline phases as sustained-release oral drug delivery systems for poorly water-soluble drugs II. In-vivo evaluation. J Pharm Pharmacol 2010, 62:856-865.
21. Final report on the safety assessment of phytantriol. Int. J. Toxicol. 2007, 26:107-114.
22. US Department of Agriculture. Glycerol monooleate processing. (accessed on 12 Nov, 2013). http://www.ams.usda.gov/AMSv1.0/getfile?dDocName=STELPRDC5057603.
23. Jain A.K., Swarnakar N.K., Das M., Godugu C., Singh R.P., Rao P.R., et al. Augmented anticancer efficacy of doxorubicin-loaded polymeric nanoparticles after oral administration in a breast cancer induced animal model. Mol Pharmaceutics 2011, 8:1140-1151.
24. Swarnakar N.K., Jain A.K., Singh R.P., Godugu C., Das M., Jain S. Oral bioavailability, therapeutic efficacy and reactive oxygen species scavenging properties of coenzyme Q10-loaded polymeric nanoparticles. Biomaterials 2011, 32:6860-6874.
25. Spicer P.T., Hayden K.L., Lynch M.L., Ofori-Boateng A., Burns J.L. Novel process for producing cubic liquid crystalline nanoparticles (cubosomes). Langmuir 2001, 17:5748-5756.
26. Jain AK, Thanki K, Jain S. Solidified Self-nanoemulsifying formulation for oral delivery of combinatorial therapeutic regimen: Part II in vivo pharmacokinetics, antitumor efficacy and hepatotoxicity. Pharm. Res. 2013;In press:10.1007/s11095-013-1214-1.
27. Swarnakar N.K., Thanki K., Jain S. Effect of co-administration of CoQ10-loaded nanoparticles on the efficacy and cardiotoxicity of doxorubicin-loaded nanoparticles. RSC Advances 2013, 3:14671.
28. Fu Z., Guo J., Jing L., Li R., Zhang T., Peng S. Enhanced toxicity and ROS generation by doxorubicin in primary cultures of cardiomyocytes from neonatal metallothionein-I/II null mice. Toxicol In Vitro 2010, 24:1584-1591.
29. Linnane A.W., Kios M., Vitetta L. Coenzyme Q(10) - its role as a prooxidant in the formation of superoxide anion/hydrogen peroxide and the regulation of the metabolome. Mitochondrion 2007, 7(Suppl.):S51-S61.
30. Jain AK, Thanki K, Jain S. Novel self-nanoemulsifying formulation of quercetin: implications of pro-oxidant activity on the anticancer efficacy. Nanomedicine. 2014;In press:10.1016/j.nano.2013.12.010.
31. Vichai V., Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 2006, 1:1112-1116.
32. Chang T.T., Chou T.C. Rational approach to the clinical protocol design for drug combinations: a review. Acta Paediatr Taiwan 2000, 41:294-302.
33. Chou T.C., Motzer R.J., Tong Y., Bosl G.J. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 1994, 86:1517-1524.
34. Jain S., Kumar D., Swarnakar N.K., Thanki K. Polyelectrolyte stabilized multilayered liposomes for oral delivery of paclitaxel. Biomaterials 2012, 33:6758-6768.
35. Jain A.K., Thanki K., Jain S. Co-encapsulation of tamoxifen and quercetin in polymeric nanoparticles: implications on oral bioavailability, antitumor efficacy, and drug-induced toxicity. Mol Pharmaceutics 2013, 10:3459-3474.
36. Jain A.K., Swarnakar N.K., Godugu C., Singh R.P., Jain S. The effect of the oral administration of polymeric nanoparticles on the efficacy and toxicity of tamoxifen. Biomaterials 2011, 32:503-515.
37. Jain S., Patil S.R., Swarnakar N.K., Agrawal A.K. Oral delivery of doxorubicin using novel polyelectrolyte-stabilized liposomes (layersomes). Mol Pharmaceutics 2012, 9:2626-2635.
38. Lee K.W., Nguyen T.H., Hanley T., Boyd B.J. Nanostructure of liquid crystalline matrix determines in vitro sustained release and in vivo oral absorption kinetics for hydrophilic model drugs. Int J Pharm 2009, 365:190-199.
39. Nguyen T.H., Hanley T., Porter C.J., Boyd B.J. Nanostructured liquid crystalline particles provide long duration sustained-release effect for a poorly water soluble drug after oral administration. J Control Rel 2011, 153:180-186.
40. Izzotti A., Camoirano A., Cartiglia C., Grubbs C.J., Lubet R.A., Kelloff G.J., et al. Patterns of DNA adduct formation in liver and mammary epithelial cells of rats treated with 7,12-dimethylbenz(a)anthracene, and selective effects of chemopreventive agents. Cancer Res 1999, 59:4285-4290.
41. Folkman J. What is the evidence that tumors are angiogenesis dependent?. J Natl Cancer Inst 1990, 82:4-7.
42. Jain S., Jain A.K., Pohekar M., Thanki K. Novel self-emulsifying formulation of quercetin for improved in vivo antioxidant potential: implications for drug-induced cardiotoxicity and nephrotoxicity. Free Radic Biol Med 2013, 65C:117-130.
43. Acharya S., Sahoo S.K. PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv Drug Deliv Rev 2011, 63:170-183.
44. Zhang Z., Ma L., Jiang S., Liu Z., Huang J., Chen L., et al. A self-assembled nanocarrier loading teniposide improves the oral delivery and drug concentration in tumor. J Control Rel 2013, 166:30-37.